Case Study: Rapid Dose-to-Clinic Delivery Through Accelerated GMP Manufacturing

A Japanese pharma company required rapid Phase I clinical progression with an aggressive multi-cohort dosing strategy. Standard manufacturing timelines of 2-3 weeks would not support the required dose escalation schedule, creating a need for clinical supply delivery within four days of dose selection.

At Arcinova, we implemented an accelerated GMP manufacturing strategy, streamlining documentation, QA, QC, and release workflows to reduce timelines from weeks to hours. This enabled a 48-hour turnaround from dose decision to clinical site supply, supporting rapid cohort progression while maintaining GMP compliance.

Download the case study to learn how Arcinova delivered agile clinical supply at the speed of the study.